Slavomíra Néčová
Research Subjects
Research Interests
Slavomíra Néčová has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Megan Work
Department of Internal medicine Wear Referrals, part of Linnaeus Veterinary Bradbury UK
1 shared publication Naomi Earley
Department of Diagnostic imaging Wear Referrals, part of Linnaeus Veterinary Bradbury UK
1 shared publicationSl Mason
Small Animal Oncology Southfields Veterinary Specialists (formerly VRCC) Laindon SS15 6TP UK
1 shared publicationSm North
Small Animal Oncology Southfields Veterinary Specialists (formerly VRCC) Laindon SS15 6TP UK
1 shared publicationSmita Das
Davies Veterinary Specialists, Higham Gobion, UK
1 shared publication- Stephen D. Cahalan
Comparative Neuromuscular Disease Laboratory, Department of Clinical Sciences and Services, Royal Veterinary College, University of London, London, UK
1 shared publication
Latest Publications
- 2 March 2026
- Published by Wiley in Veterinary Record Case Reports
- Vol. 14 (2)
High T‐cell lymphoma of the vulva in a female dog
Extra‐nodal lymphoma of the female genital system in dogs is extremely rare. In this case report, we describe a case of genital lymphoma with involvement of the regional lymph nodes in a 10‐year‐old, female, neutered Samoyed. Dog presented with a 4‐week history of an oedematous and erythematous vulva. Additionally, on clinical examination, popliteal and inguinal lymphadenomegaly and a right‐sided vulvar mass were detected. Cytology of the popliteal lymph node and vulvar mass revealed a monomorphic population of large lymphocytes; flow cytometry performed on the enlarged lymph nodes confirmed the diagnosis of high‐grade T‐cell lymphoma. Due to worsening of the clinical signs and concerns regarding quality of life, the owners elected for euthanasia while the results were pending. This is an unusual presentation of T‐cell lymphoma of the vulva and regional lymph nodes and represents an important differential diagnosis for oedema of external genitals and local lymphadenomegaly in female dogs.
- 2 March 2026
- Published by Wiley in Veterinary Record Case Reports
- Vol. 14 (2)
High T‐cell lymphoma of the vulva in a female dog
Extra‐nodal lymphoma of the female genital system in dogs is extremely rare. In this case report, we describe a case of genital lymphoma with involvement of the regional lymph nodes in a 10‐year‐old, female, neutered Samoyed. Dog presented with a 4‐week history of an oedematous and erythematous vulva. Additionally, on clinical examination, popliteal and inguinal lymphadenomegaly and a right‐sided vulvar mass were detected. Cytology of the popliteal lymph node and vulvar mass revealed a monomorphic population of large lymphocytes; flow cytometry performed on the enlarged lymph nodes confirmed the diagnosis of high‐grade T‐cell lymphoma. Due to worsening of the clinical signs and concerns regarding quality of life, the owners elected for euthanasia while the results were pending. This is an unusual presentation of T‐cell lymphoma of the vulva and regional lymph nodes and represents an important differential diagnosis for oedema of external genitals and local lymphadenomegaly in female dogs.
- 9 February 2021
- Published by Wiley in Australian Veterinary Journal
- Vol. 99 (5) , 146-151
Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine
Objectives The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Animals Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. Procedures Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re‐staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease‐free interval (DFI) and median survival time (MST) were calculated using Kaplan–Meier method. Results Twenty‐one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow‐up period of the whole study population was 1112 days (358–2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One‐year and 2‐year survivals were 95.2% and 90.5%, respectively. Conclusions and clinical relevance This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.
- 9 February 2021
- Published by Wiley in Australian Veterinary Journal
- Vol. 99 (5) , 146-151
Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine
Objectives The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Animals Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. Procedures Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re‐staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease‐free interval (DFI) and median survival time (MST) were calculated using Kaplan–Meier method. Results Twenty‐one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow‐up period of the whole study population was 1112 days (358–2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One‐year and 2‐year survivals were 95.2% and 90.5%, respectively. Conclusions and clinical relevance This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.
- Open Access
- 1 July 2020
- Published by SAGE Publications in Journal of Feline Medicine and Surgery Open Reports
- Vol. 6 (2)
Oral histiocytic sarcoma in a cat
Case summary: A 15-year-old neutered male domestic shorthair cat presented with a 4-week history of dysphonia and reluctance to chew hard food. Oral examination revealed a mass lesion on the caudal soft palate. Biopsy was performed and histopathology with immunohistochemistry was most consistent with histiocytic sarcoma. CT of the head identified a discrete, left-sided, soft tissue mass lesion cranial to the tonsil with bilaterally symmetrical regional lymph nodes. CT of the thorax was unremarkable. Surgical removal achieved cytoreduction but not complete removal. Adjuvant chemotherapy with lomustine 10 mg (30 mg/m2) was initiated. The patient developed suspected pancreatitis 2–3 weeks postoperatively, so further chemotherapy treatment was discontinued, but supportive treatment with pain relief and appetite stimulants was provided. Three months postoperatively, the patient developed recurrent dysphonia, and oral examination revealed a suspicion of local recurrence. Confirmation of diagnosis (cytopathology or histopathology) was not obtained. Supportive treatment to maintain a good quality of life was continued and the patient was euthanased 6 months after diagnosis owing to progressive disease. Relevance and novel information: Only a few reports have been published describing histiocytic diseases of cats. To our knowledge, this is the first report of a feline histiocytic sarcoma of the oral cavity. Therefore, histiocytic sarcoma should be considered as a differential diagnosis in feline patients with an oral mass, especially if histopathology suggests a pleomorphic and poorly differentiated sarcoma. Immunohistochemistry for the confirmation of cell line origin would be strongly recommended.
- 1 July 2020
- Published by SAGE Publications in Journal of Feline Medicine and Surgery Open Reports
- Vol. 6 (2)
Open AccessOral histiocytic sarcoma in a cat
Case summary: A 15-year-old neutered male domestic shorthair cat presented with a 4-week history of dysphonia and reluctance to chew hard food. Oral examination revealed a mass lesion on the caudal soft palate. Biopsy was performed and histopathology with immunohistochemistry was most consistent with histiocytic sarcoma. CT of the head identified a discrete, left-sided, soft tissue mass lesion cranial to the tonsil with bilaterally symmetrical regional lymph nodes. CT of the thorax was unremarkable. Surgical removal achieved cytoreduction but not complete removal. Adjuvant chemotherapy with lomustine 10 mg (30 mg/m2) was initiated. The patient developed suspected pancreatitis 2–3 weeks postoperatively, so further chemotherapy treatment was discontinued, but supportive treatment with pain relief and appetite stimulants was provided. Three months postoperatively, the patient developed recurrent dysphonia, and oral examination revealed a suspicion of local recurrence. Confirmation of diagnosis (cytopathology or histopathology) was not obtained. Supportive treatment to maintain a good quality of life was continued and the patient was euthanased 6 months after diagnosis owing to progressive disease. Relevance and novel information: Only a few reports have been published describing histiocytic diseases of cats. To our knowledge, this is the first report of a feline histiocytic sarcoma of the oral cavity. Therefore, histiocytic sarcoma should be considered as a differential diagnosis in feline patients with an oral mass, especially if histopathology suggests a pleomorphic and poorly differentiated sarcoma. Immunohistochemistry for the confirmation of cell line origin would be strongly recommended.